Breaking Barriers: XJTU Hospital's Multidisciplinary Team Saves Central Asian Patient with Malignant Blood Disease
When a Patient Crosses Borders for Life-Saving Treatment
For patients in Central Asia facing aggressive blood cancers, local treatment options can be limited. Advanced therapies — targeted drugs, novel immunotherapies, and complex transplant protocols — may simply not be available. When a patient from Central Asia was diagnosed with a severe malignant hematological disease, the search for treatment led to Xi'an Jiaotong University First Affiliated Hospital (XJTU-FAH) in China.
What followed was a demonstration of everything that makes China's top hospitals increasingly attractive to international patients: rapid multidisciplinary mobilization, advanced treatment protocols, compassionate cross-cultural care, and costs that are a fraction of Western alternatives.
The Multidisciplinary Approach
XJTU-FAH assembled a multidisciplinary team spanning hematology, oncology, infectious disease, and supportive care to design a comprehensive treatment protocol. The challenges of treating an international patient extended beyond medicine:
- Language coordination — Medical interpreters and bilingual staff ensured clear communication at every stage
- Treatment planning — Protocols adapted to account for the patient's previous treatments and genetic background
- Cultural sensitivity — Dietary requirements, family involvement preferences, and religious considerations respected throughout
- Continuity of care — Discharge planning included detailed instructions and follow-up coordination with the patient's home country physicians
The Outcome
The patient responded well to treatment and was able to return home with a clear follow-up plan. The case was recognized within the hospital as a model for cross-border medical collaboration, earning commendation from both the medical team and the patient's family.
Why International Patients Choose China for Blood Cancer Treatment
| Factor | China | Western Countries | Central/South Asia |
|---|---|---|---|
| CAR-T therapy availability | Multiple approved products | Available but extremely expensive | Limited or unavailable |
| Bone marrow transplant cost | $30,000 - $60,000 | $200,000 - $500,000 | $20,000 - $40,000 (limited centers) |
| Wait time | Weeks | Months | Variable |
| Novel clinical trials | Extensive | Extensive | Very limited |
About XJTU First Affiliated Hospital
- Affiliated with Xi'an Jiaotong University — C9 League, top-15 Chinese university
- Hematology department with comprehensive transplant and immunotherapy capabilities
- Growing international patient services with multilingual coordination
- Located in Xi'an — SinomedTrip's home city
Seeking advanced blood cancer treatment? Request a free hematology consultation →
